CCL2 and prostate carcinoma: Kai Sha and collaborators proved that a TNFα–CCL2 paracrine loop is induced in response to androgen deprivation therapy with enzalutamide in prostate cancer patients and might account for some forms of prostate cancer therapy resistance.